Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | PHASE1 | ACTIVE NOT_RECRUITING | 45 | — | — | Dec 31, 2021 | Dec 1, 2025 | Aug 8, 2025 | 22 | United States, United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Part A: Dose Escalation | EXPERIMENTAL | Escalating doses of NXP800 administered orally once or twice daily. |
| Part B: Expansion in Ovarian Cancers Cohort 1 | EXPERIMENTAL | Subjects will be treated with NXP800 at 50 mg/day orally. |
| Part B: Expansion in Ovarian Cancers Cohort 2 | EXPERIMENTAL | Subjects will be treated with NXP800 at 75 mg/day orally. |
| Name | Type | Description |
|---|---|---|
| NXP800 | DRUG | NXP800 is an anti-neoplastic, oral small molecule. |
Part A Inclusion Criteria: * Provide written informed consent. * 18 years old or older. * Life expectancy of at least 12 weeks. * Histologically- or cytologically-confirmed, advanced, metastatic, and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |